We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
-6.2%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$26.3M
AUM Growth
-$8.33M
Cap. Flow
-$5.28M
Cap. Flow %
-20.05%
Top 10 Hldgs %
100%
Holding
9
New
2
Increased
3
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$275K
2
ACRS icon
Aclaris Therapeutics
ACRS
+$166K
3
ALLK
Allakos
ALLK
+$117K
4
CMPX icon
Compass Therapeutics
CMPX
+$107K
5
ELEV
Elevation Oncology
ELEV
+$89

Top Sells

Rank Stock Value
1
SVRA icon
Savara
SVRA
+$5.94M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
1
Savara
SVRA
$1.13B
$12.5M 47.59%
3,313,602
-1,667,202
-33% -$5.94M
XERS icon
2
Xeris Biopharma Holdings
XERS
$1.5B
$10.5M 39.87%
5,641,920
– –
RZLT icon
3
Rezolute
RZLT
$421M
$1.74M 6.61%
1,318,967
– –
MTEM
4
DELISTED
Molecular Templates, Inc.
MTEM
$865K 3.29%
136,866
– –
APGE icon
5
Apogee Therapeutics
APGE
$10.1B
$266K 1.01%
+12,472
New +$275K
CMPX icon
6
Compass Therapeutics
CMPX
$378M
$171K 0.65%
86,773
+43,307
+100% +$107K
ACRS icon
7
Aclaris Therapeutics
ACRS
$749M
$133K 0.51%
+19,473
New +$166K
ALLK
8
DELISTED
Allakos
ALLK
$112K 0.43%
49,329
+31,596
+178% +$117K
ELEV
9
DELISTED
Elevation Oncology
ELEV
$14.5K 0.05%
21,813
+88
+0.4% +$89

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q3 2023 Portfolio in Review

As of Q3 2023, Caxton Corporation held 9 positions worth $26.3M, down 24% from $34.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caxton Corporation withdrew a net $5.28M in Q3 2023, reducing 1 holding. Its largest reduction was Savara, cutting an estimated $5.94M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Caxton Corporation opened a new position in Apogee Therapeutics worth $266K.

  • Caxton Corporation's largest Q3 2023 buy was Apogee Therapeutics: 12,472 shares worth $266K.
  • Caxton Corporation added most to Allakos in Q3 2023, an estimated $117K increase.
  • Caxton Corporation's biggest Q3 2023 reduction was Savara, cutting an estimated $5.94M.
  • Caxton Corporation's ten largest holdings make up 100% of its $26.3M portfolio in Q3 2023.
  • Caxton Corporation opened 2 new positions and closed 0 in Q3 2023.
  • Caxton Corporation's portfolio value fell 24% quarter-over-quarter to $26.3M.

Based on Caxton Corporation's 13F filing for Q3 2023, filed 14 Nov 2023.